Exelixis, Inc. SEC filings EXEL
Exelixis, Inc. has 1,003 filings in SEC EDGAR's recent list, going back to Mar 2, 2018. Its latest annual report, Form 10-K, was filed on Feb 10, 2026 for the period ended Jan 2, 2026. The latest quarterly report (Form 10-Q) was filed on Oct 29, 2026, covering the quarter ended Oct 2, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (results of operations). The company's fiscal year ends on January 1.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 17, 2026 | — |
| DEFA14A | Additional proxy material | Apr 15, 2026 | — |
| DEF 14A | Proxy statement | Apr 15, 2026 | May 26, 2026 |
| DEFA14A | Additional proxy material | Apr 16, 2025 | — |
| DEF 14A | Proxy statement | Apr 16, 2025 | May 28, 2025 |
| DEFA14A | Additional proxy material | Apr 18, 2024 | — |
| DEF 14A | Proxy statement | Apr 18, 2024 | May 30, 2024 |
| DEFA14A | Additional proxy material | May 17, 2023 | — |
| DEFA14A | Additional proxy material | May 15, 2023 | — |
| DEFA14A | Additional proxy material | May 8, 2023 | — |
| DEFA14A | Additional proxy material | May 2, 2023 | — |
| DEFA14A | Additional proxy material | May 1, 2023 | — |
| DEFA14A | Additional proxy material | Apr 13, 2023 | — |
| DEFA14A | Additional proxy material | Apr 6, 2023 | — |
| DEFA14A | Additional proxy material | Apr 14, 2022 | — |
| DEF 14A | Proxy statement | Apr 14, 2022 | May 25, 2022 |
| DEFA14A | Additional proxy material | Apr 15, 2021 | — |
| DEF 14A | Proxy statement | Apr 15, 2021 | May 26, 2021 |
| DEFA14A | Additional proxy material | Apr 9, 2020 | — |
| DEF 14A | Proxy statement | Apr 9, 2020 | May 20, 2020 |
| DEFA14A | Additional proxy material | May 8, 2019 | — |
| DEFA14A | Additional proxy material | May 8, 2019 | — |
| DEFA14A | Additional proxy material | Apr 11, 2019 | — |
| DEF 14A | Proxy statement | Apr 11, 2019 | May 22, 2019 |
| PRE 14A | Preliminary proxy statement | Mar 28, 2019 | May 22, 2019 |
| DEFA14A | Additional proxy material | Apr 12, 2018 | — |
| DEF 14A | Proxy statement | Apr 12, 2018 | May 23, 2018 |
Showing 27 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- EXEL (Nasdaq)
- Fiscal year ends
- January 1
- Incorporated in
- DE
- Headquarters
- Alameda, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 939767
- Former names
- EXELIXIS INC (until Sep 12, 2012)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.